Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: RCC1

Gene summary for RCC1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

RCC1

Gene ID

1104

Gene nameregulator of chromosome condensation 1
Gene AliasCHC1
Cytomap1p35.3
Gene Typeprotein-coding
GO ID

GO:0000082

UniProtAcc

A0A0S2Z404


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
1104RCC1LZE4THumanEsophagusESCC5.76e-047.72e-020.0811
1104RCC1LZE8THumanEsophagusESCC6.08e-041.90e-010.067
1104RCC1LZE20THumanEsophagusESCC1.40e-021.44e-010.0662
1104RCC1LZE22THumanEsophagusESCC4.75e-066.62e-010.068
1104RCC1LZE24THumanEsophagusESCC1.83e-093.92e-010.0596
1104RCC1LZE6THumanEsophagusESCC1.28e-022.94e-010.0845
1104RCC1P1T-EHumanEsophagusESCC1.12e-137.63e-010.0875
1104RCC1P2T-EHumanEsophagusESCC1.18e-411.05e+000.1177
1104RCC1P4T-EHumanEsophagusESCC1.32e-401.10e+000.1323
1104RCC1P5T-EHumanEsophagusESCC4.84e-378.63e-010.1327
1104RCC1P8T-EHumanEsophagusESCC8.89e-419.26e-010.0889
1104RCC1P9T-EHumanEsophagusESCC1.81e-318.80e-010.1131
1104RCC1P10T-EHumanEsophagusESCC3.16e-621.23e+000.116
1104RCC1P11T-EHumanEsophagusESCC2.47e-137.90e-010.1426
1104RCC1P12T-EHumanEsophagusESCC9.73e-378.13e-010.1122
1104RCC1P15T-EHumanEsophagusESCC1.10e-327.94e-010.1149
1104RCC1P16T-EHumanEsophagusESCC3.81e-184.84e-010.1153
1104RCC1P17T-EHumanEsophagusESCC2.92e-157.90e-010.1278
1104RCC1P19T-EHumanEsophagusESCC4.29e-071.00e+000.1662
1104RCC1P20T-EHumanEsophagusESCC1.58e-411.19e+000.1124
Page: 1 2 3 4 5 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:20000585ColorectumCRCregulation of ubiquitin-dependent protein catabolic process40/2078164/187231.12e-066.69e-0540
GO:19033625ColorectumCRCregulation of cellular protein catabolic process53/2078255/187234.58e-061.87e-0453
GO:00434344ColorectumCRCresponse to peptide hormone76/2078414/187236.67e-062.56e-0476
GO:00328684ColorectumCRCresponse to insulin53/2078264/187231.30e-054.17e-0453
GO:00063254ColorectumCRCchromatin organization74/2078409/187231.48e-054.61e-0474
GO:00329845ColorectumCRCprotein-containing complex disassembly46/2078224/187232.61e-057.18e-0446
GO:19030505ColorectumCRCregulation of proteolysis involved in cellular protein catabolic process45/2078221/187233.96e-059.60e-0445
GO:00016552ColorectumCRCurogenital system development62/2078338/187234.67e-051.10e-0362
GO:00328694ColorectumCRCcellular response to insulin stimulus42/2078203/187234.79e-051.12e-0342
GO:00713754ColorectumCRCcellular response to peptide hormone stimulus55/2078290/187234.82e-051.12e-0355
GO:19016534ColorectumCRCcellular response to peptide64/2078359/187238.54e-051.75e-0364
GO:00614584ColorectumCRCreproductive system development73/2078427/187231.13e-042.22e-0373
GO:00224115ColorectumCRCcellular component disassembly75/2078443/187231.26e-042.42e-0375
GO:20000595ColorectumCRCnegative regulation of ubiquitin-dependent protein catabolic process15/207848/187231.40e-042.61e-0315
GO:19033635ColorectumCRCnegative regulation of cellular protein catabolic process20/207875/187231.42e-042.62e-0320
GO:19030515ColorectumCRCnegative regulation of proteolysis involved in cellular protein catabolic process18/207864/187231.44e-042.64e-0318
GO:00486084ColorectumCRCreproductive structure development72/2078424/187231.55e-042.80e-0372
GO:00431615ColorectumCRCproteasome-mediated ubiquitin-dependent protein catabolic process69/2078412/187233.16e-044.90e-0369
GO:00324345ColorectumCRCregulation of proteasomal ubiquitin-dependent protein catabolic process28/2078134/187236.94e-049.05e-0328
GO:00104985ColorectumCRCproteasomal protein catabolic process77/2078490/187231.03e-031.21e-0277
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
RCC1insertionFrame_Shift_Insnovelc.781_782insTACTCp.Met261IlefsTer4p.M261Ifs*4P18754protein_codingTCGA-AO-A0JD-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapycyclophosphamideSD
RCC1insertionFrame_Shift_Insnovelc.783_784insAACATAGTTTCTTCATCACTAAGTCTACCTACp.Leu262AsnfsTer12p.L262Nfs*12P18754protein_codingTCGA-AO-A0JD-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapycyclophosphamideSD
RCC1SNVMissense_Mutationnovelc.98N>Ap.Arg33Hisp.R33HP18754protein_codingtolerated(0.24)benign(0.182)TCGA-A6-3809-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
RCC1SNVMissense_Mutationc.1051N>Tp.Arg351Trpp.R351WP18754protein_codingdeleterious(0.02)probably_damaging(0.997)TCGA-AA-3715-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownPD
RCC1SNVMissense_Mutationrs528320406c.743G>Ap.Arg248Glnp.R248QP18754protein_codingdeleterious(0)possibly_damaging(0.607)TCGA-AA-3864-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
RCC1SNVMissense_Mutationrs760969624c.1186C>Tp.Arg396Cysp.R396CP18754protein_codingtolerated(0.12)benign(0.025)TCGA-G4-6309-01Colorectumcolon adenocarcinomaFemale<65III/IVChemotherapyxelodaPD
RCC1SNVMissense_Mutationrs745611564c.1025C>Tp.Ser342Leup.S342LP18754protein_codingdeleterious(0.05)benign(0.147)TCGA-AG-A002-01Colorectumrectum adenocarcinomaMale<65I/IIUnknownUnknownSD
RCC1deletionFrame_Shift_Delc.32delNp.Pro13GlnfsTer11p.P13Qfs*11P18754protein_codingTCGA-AA-3492-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
RCC1deletionFrame_Shift_Delc.32delNp.Pro13GlnfsTer11p.P13Qfs*11P18754protein_codingTCGA-AA-3663-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
RCC1deletionFrame_Shift_Delc.38delCp.Pro13GlnfsTer11p.P13Qfs*11P18754protein_codingTCGA-AA-3710-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1